<DOC>
	<DOCNO>NCT00306319</DOCNO>
	<brief_summary>Pharmacokinetic study TB patient determine effect rifampicin pharmacokinetic profile moxifloxacin .</brief_summary>
	<brief_title>Pharmacokinetic Interaction Study Indonesian Tuberculosis Patients Indonesia</brief_title>
	<detailed_description>Tuberculosis infectious disease still cause many victim develop world , especially Indonesia . Rifampicin , isoniazid ethambutol cornerstone current treatment . The disadvantage current treatment long , six-months , duration treatment . This long duration contributes suboptimal adherence TB drugs.Thus , urgent need evaluate drug may help shorten TB treatment . The fluoroquinolone moxifloxacin show early bactericidal activity ( EBA ) patient pulmonary TB , show rapid reliable sterilization . Rifampicin strong inducer CYP enzyme , also induce phase II metabolism . As moxifloxacin metabolize phase II metabolism , rifampicin could cause decrease plasma concentration moxifloxacin . Therefore , pharmacokinetic interaction study warrant .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Indonesian AFB negative tuberculosis patient last two month continuation phase sixmonthantituberculosis treatment . Subject 1855 year age day first dose study medication . Subject normal ECG Subjects bodyweight &gt; 35kg Use rifampicin isoniazid Pregnant lactate History condition might interfere drug absorption , distribution , metabolism excretion , include ileus , gastric paresis , liver renal dysfunction , diabetes mellitus . Presence contraindication moxifloxacin use drug know interact moxifloxacin . Subject able and/or willing sign inform consent form .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>Tuberculosis</keyword>
</DOC>